0.00Open0.35Pre Close0 Volume3 Open Interest20.00Strike Price0.00Turnover0.00%IV18.38%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma49.11Leverage Ratio--Theta--Rho--Eff Leverage--Vega
AxoGen Stock Discussion
loading...
looks like more 💰flow and narrower loss this years looks interesting here
In reaction to earnings/guidance:
• $Silvergate Capital (SI.US)$ +10.7% (Silvergate (ticker: SI) notched net income of $38.6 million in the June quarter, delivering earnings per share (EPS) of $1.13.)
• $AxoGen (AXGN.US)$ +3.3% (guides Q2 revs above consensus; also makes changes to its commercial organization),
• $Novartis AG (NVS.US)$ + 3% (The Swiss pharmaceutical company on Tuesday posted net profit of $1.69 billion, down from...
• $Intercept Pharmaceuticals (ICPT.US)$ +25.7% (to sell license to commercialize Ocaliva outside the US to Advanz Pharma for upfront payment of $405 mln)
• $Albemarle (ALB.US)$ +13.9% (earnings reports)
• $Booking Holdings (BKNG.US)$ +10% (Booking Holdings' Outlook for a 'Busy' summer season drives the stock sharply higher)
• $AxoGen (AXGN.US)$ +9% (reports top-line results from RECON study of Avance Nerge Graft)
• $Cumulus Media (CMLS.US)$ +7.2% (an...
No comment yet